Valneva SE
NASDAQ:VALN

Watchlist Manager
Valneva SE Logo
Valneva SE
NASDAQ:VALN
Watchlist
Price: 9.89 USD 1.44%
Market Cap: 688.1m USD

Net Margin
Valneva SE

-43.8%
Current
-24%
Average
-6.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-43.8%
=
Net Income
-120.2m
/
Revenue
274.6m

Net Margin Across Competitors

No Stocks Found

Valneva SE
Glance View

Market Cap
688.1m USD
Industry
Biotechnology

Valneva SE is a biotech company. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 722 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

VALN Intrinsic Value
HIDDEN
Show
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-43.8%
=
Net Income
-120.2m
/
Revenue
274.6m
What is the Net Margin of Valneva SE?

Based on Valneva SE's most recent financial statements, the company has Net Margin of -43.8%.

Back to Top